Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|August 10, 2026 (Updated: August 10, 2026)

The BioPharm Brief: Targets, Technology, and Timing

Listen
0:00 / 0:00

Today’s BioPharm Brief looks at Akeso’s bispecific ADC and ivonescimab combination in breast cancer, Novo Nordisk’s AI partnership with AWS, and Ascletis’ once-monthly obesity candidates.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry.

What do cancer treatment, artificial intelligence, and obesity drug development have in common? All three are being pushed toward greater precision, whether that means targeting multiple tumor proteins, using AI to rethink drug discovery, or combining metabolic pathways in longer-acting therapies.

First, Akeso has dosed the first patient in a phase 2 trial evaluating AK146D1, a bispecific antibody-drug conjugate, in combination with ivonescimab for advanced breast cancer.

The study is evaluating the combination as a first-line treatment for patients with hormone receptor-positive, HER2-negative breast cancer and triple-negative breast cancer. AK146D1 is designed to simultaneously target TROP2 and Nectin-4, two proteins expressed on tumor cells. Akeso is positioning the program as part of an “IO2.0 plus ADC2.0” strategy, with the broader goal of combining next-generation ADCs with immuno-oncology therapies.

Next, AI is moving deeper into the drug discovery process.

Novo Nordisk and Amazon Web Services have announced a strategic partnership aimed at using artificial intelligence and cloud technologies to accelerate drug discovery and development.

The collaboration will use AWS tools including Amazon Bio Discovery, Amazon Bedrock, and Bedrock AgentCore. The companies have not yet disclosed specific timelines for AI-assisted drug programs to produce new therapies. The potential impact on drug development may take years to measure.

And finally, in obesity research, Ascletis is testing whether longer-acting peptide therapies can combine multiple metabolic pathways while reducing injection frequency. The company has initiated two phase 1 studies in the US, one evaluating ASC36, a once-monthly to once-quarterly amylin receptor agonist, and another evaluating ASC36_35FDC, a once-monthly fixed-dose combination of ASC36 with ASC35, a GLP-1 and GIP receptor dual agonist.

The combination is designed to target three pathways, amylin, GLP-1, and GIP, in a single injection that is designed to create a depot under the skin that gradually releases the drug over a month or longer. The phase 1 trials will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics following single and multiple ascending doses.

What happens next will depend on the data. Akeso’s phase 2 study, Novo Nordisk’s expanding use of AI, and Ascletis’ early clinical work will each have to show that these approaches can deliver meaningful results beyond the technology itself.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key takeaways:

  • Akeso has begun Phase 2 testing of a bispecific ADC and ivonescimab combination in breast cancer.
  • Novo Nordisk and AWS are expanding AI use across drug discovery and development.
  • Ascletis has entered Phase 1 testing of longer-acting amylin and incretin therapies for obesity.

Related to this article

View more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more